Full Title
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant CancersPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Anupriya Singhal’s office at 646-888-4302.
Protocol
26-309
Phase
Phase I (phase 1)
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06917079
ClinicalTrials.gov